Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder
Hutton, Todd M
West, W Scott
MetadataShow full item record
AbstractBackground: Transcranial magnetic stimulation (TMS) is an effective treatment for major depressive disorder (MDD). The rest time between pulse trains is the inter-train interval (ITI). Since 2016, some TMS clinicians have adopted a stimulation protocol with shorter ITIs than were used in regulatory clinical trials. Objective: To contrast treatment outcomes with the Standard TMS protocol (38.5 min per session) and the “Dash” protocol, which, at the shortest ITI, has a session duration of 18.75 min. Methods: Registry data were collected at 103 practice sites. Of 7759 participants, 5010 were included in an intent-to-treat (ITT) sample, defined as a primary MDD diagnosis, age ≥ 18, and completion of the PHQ-9 before TMS and with at least one PHQ-9 assessment after baseline. Completers (N = 3814) were responders or had received ≥ 20 sessions and had an end of acute treatment PHQ-9 assessment. Within the ITT sample, 613 patients were treated with the Standard NeuroStar 38-min protocol and 1493 patients with the new Dash protocol. CGI-S ratings were obtained in smaller samples. Treatment outcomes were also examined in subgroups considered Completers, as well as the subgroups who met criteria for Full Adherence to the Standard or Dash protocol parameters. Results: In the ITT, Completer, and Fully Adherent samples, response (58–72%) and remission (28–53%) rates were notably high across PHQ-9 and CGI-S ratings. The Standard and Dash protocols did not differ in number of treatment sessions, and both manifested strong antidepressant effects. Conclusions: The Standard and Dash protocols did not meaningfully differ in efficacy.
Rights/TermsCopyright © 2020. Published by Elsevier Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14315
- Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation.
- Authors: Sackeim HA, Aaronson ST, Carpenter LL, Hutton TM, Mina M, Pages K, Verdoliva S, West WS
- Issue date: 2020 Dec 1
- Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice.
- Authors: Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA
- Issue date: 2012 Jul
- Behavioral activation therapy during transcranial magnetic stimulation for major depressive disorder.
- Authors: Russo GB, Tirrell E, Busch A, Carpenter LL
- Issue date: 2018 Aug 15
- Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
- Authors: Connolly KR, Helmer A, Cristancho MA, Cristancho P, O'Reardon JP
- Issue date: 2012 Apr
- Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder.
- Authors: Kim DR, Wang E, McGeehan B, Snell J, Ewing G, Iannelli C, O'Reardon JP, Sammel MD, Epperson CN
- Issue date: 2019 Jan - Feb